These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 34029540)
21. Enhanced Antitumor Efficacy of Curcumin-Loaded PLGA Nanoparticles Coated with Unique Fungal Hydrophobin. Sun L; Xu H; Xu JH; Wang SN; Wang JW; Zhang HF; Jia WR; Li LS AAPS PharmSciTech; 2020 Jun; 21(5):171. PubMed ID: 32529560 [TBL] [Abstract][Full Text] [Related]
22. Tetrac-decorated chitosan-coated PLGA nanoparticles as a new platform for targeted delivery of SN38. Alibolandi M; Amel Farzad S; Mohammadi M; Abnous K; Taghdisi SM; Kalalinia F; Ramezani M Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1003-1014. PubMed ID: 29806500 [TBL] [Abstract][Full Text] [Related]
23. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced. Song X; Wang J; Xu Y; Shao H; Gu J Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022 [TBL] [Abstract][Full Text] [Related]
24. Cytotoxic Evaluation of (2S)-5,7-Dihydroxy-6-prenylflavanone Derivatives Loaded PLGA Nanoparticles against MiaPaCa-2 Cells. Andrade-Carrera B; Clares B; Noé V; Mallandrich M; Calpena AC; García ML; Garduño-Ramírez ML Molecules; 2017 Sep; 22(9):. PubMed ID: 28914822 [TBL] [Abstract][Full Text] [Related]
25. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Garapaty-Rao S; Nasveschuk C; Gagnon A; Chan EY; Sandy P; Busby J; Balasubramanian S; Campbell R; Zhao F; Bergeron L; Audia JE; Albrecht BK; Harmange JC; Cummings R; Trojer P Chem Biol; 2013 Nov; 20(11):1329-39. PubMed ID: 24183969 [TBL] [Abstract][Full Text] [Related]
26. A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. Wang X; Cao W; Zhang J; Yan M; Xu Q; Wu X; Wan L; Zhang Z; Zhang C; Qin X; Xiao M; Ye D; Liu Y; Han Z; Wang S; Mao L; Wei W; Chen W EMBO J; 2017 May; 36(9):1243-1260. PubMed ID: 28320739 [TBL] [Abstract][Full Text] [Related]
27. Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR. Ansari A; Satalkar S; Patil V; Shete AS; Kaur S; Gupta A; Singh S; Raja M; Severance DL; Bernales S; Chakravarty S; Hung DT; Pham SM; Herrera FJ; Rai R Bioorg Med Chem Lett; 2017 Jan; 27(2):217-222. PubMed ID: 27923618 [TBL] [Abstract][Full Text] [Related]
28. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance. Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193 [TBL] [Abstract][Full Text] [Related]
29. Purine-benzimidazole hybrids: synthesis, single crystal determination and in vitro evaluation of antitumor activities. Sharma A; Luxami V; Paul K Eur J Med Chem; 2015 Mar; 93():414-22. PubMed ID: 25728022 [TBL] [Abstract][Full Text] [Related]
30. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors. Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of anti-cancer activity of PLGA nanoparticles containing crocetin. Hafezi Ghahestani Z; Alebooye Langroodi F; Mokhtarzadeh A; Ramezani M; Hashemi M Artif Cells Nanomed Biotechnol; 2017 Aug; 45(5):955-960. PubMed ID: 27327450 [TBL] [Abstract][Full Text] [Related]
32. 5-Methoxyquinoline Derivatives as a New Class of EZH2 Inhibitors. Xiang P; Jie H; Zhou Y; Yang B; Wang HJ; Hu J; Hu J; Yang SY; Zhao YL Molecules; 2015 Apr; 20(5):7620-36. PubMed ID: 25923513 [TBL] [Abstract][Full Text] [Related]
34. Synthesis and molecular modeling of new benzimidazoles as glutathione S-transferase inhibitors and anticancer agents. Abd El-Karim SS; Anwar MM; Zaki ER; Elseginy SA; Nofal ZM Future Med Chem; 2018 Jan; 10(2):157-181. PubMed ID: 29235906 [TBL] [Abstract][Full Text] [Related]
35. 5-Hydroxyindole-Based EZH2 Inhibitors Assembled via TCCA-Catalyzed Condensation and Nenitzescu Reactions. Du F; Zhou Q; Sun W; Yang C; Wu C; Wang L; Chen G Molecules; 2020 Apr; 25(9):. PubMed ID: 32354194 [TBL] [Abstract][Full Text] [Related]
36. Paclitaxel/methotrexate co-loaded PLGA nanoparticles in glioblastoma treatment: Formulation development and in vitro antitumor activity evaluation. Madani F; Esnaashari SS; Bergonzi MC; Webster TJ; Younes HM; Khosravani M; Adabi M Life Sci; 2020 Sep; 256():117943. PubMed ID: 32531377 [TBL] [Abstract][Full Text] [Related]
37. Synthesis, antitumor activity and SAR study of novel [1,2,4]triazino[4,5-a]benzimidazole derivatives. El-Nassan HB Eur J Med Chem; 2012 Jul; 53():22-7. PubMed ID: 22542105 [TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors. Celik İ; Ayhan-Kılcıgil G; Guven B; Kara Z; Gurkan-Alp AS; Karayel A; Onay-Besikci A Eur J Med Chem; 2019 Jul; 173():240-249. PubMed ID: 31009910 [TBL] [Abstract][Full Text] [Related]
39. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609 [TBL] [Abstract][Full Text] [Related]
40. Activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells. Wu J; Zhao S; Tang Q; Zheng F; Chen Y; Yang L; Yang X; Li L; Wu W; Hann SS J Exp Clin Cancer Res; 2015 Sep; 34(1):99. PubMed ID: 26362062 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]